Categories: BioTechDesignDrugFamilyPlatform
Orbis Medicines is a leader in oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties defined by the presence of a cyclic structure. The company's portfolio of next-generation macrocycle drugs called ‘nCycles’ are systematically designed by Orbis’ nGen platform to be orally bioavailable and membrane permeable, solving decades-long challenges in macrocycle drug design.
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.01.2025 | Series A | $93.45M | - |
| 04.03.2024 | Seed | $28.22M | - |
Mentions in press and media 8
| Date | Title | Description |
| 06.01.2025 | Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles | - Funding to support the development of pipeline of oral macrocycle drugs, called ‘nCycles,’ focused on validated blockbuster biologic targets
- Orbis’ nGen platform systematically explores oral macrocycle design with automated chemistry an... |
| 06.01.2025 | Orbis Medicines: Oral Macrocycle Drug Discovery Company Raises €90 Million (Series A) | Orbis Medicines – a leader in oral macrocycle drug discovery – announced today the closing of a €90 million Series A funding round, bringing the total amount raised by the company to €116 million. The funding round will support the developm... |
| 06.01.2025 | Orbis Medicines Raises €90M in Series A Funding | Orbis Medicines, a Copenhagen, Denmark-based oral macrocycle drug discovery company, raised €90M in Series A funding.
The round was led by NEA with participation from new investors including Eli Lilly and Company, Cormorant, the Export and ... |
| 04.03.2024 | Orbis Medicines: Oral Macrocycle Drug Discovery Company Raises €26 Million | Orbis Medicines – a leader in oral macrocycle drug discovery – announced its launch with a €26 million financing led by global life sciences investor Novo Holdings and Forbion. This funding round will support Orbis’ expansion and advancemen... |
| 01.03.2024 | Orbis Medicines Revolutionizing Oral Macrocycle Drug Discovery | Orbis Medicines, a biotech company based in Copenhagen, Denmark, is making waves in the world of drug discovery with its innovative approach to developing oral macrocycle drugs. With a recent €26M seed financing round led by Novo Holdings a... |
| 29.02.2024 | Orbis Medicines Launches with €26M Seed Financing | Orbis Medicines, a Copenhagen, Denmark-based company which specializes in oral macrocycle drug discovery, raised €26M in Seed funding.
The round was led by Novo Holdings and Forbion.
The company intends to use the funds to support the expan... |
| 29.02.2024 | Startup Orbis Medicines Launches With €26M for Next-Generation Peptide Drugs | For all of the benefit that biologic drugs provide as treatments for chronic conditions, these medications also require chronic dosing by injection or infusion. Biotech companies have been pursuing ways to hit the same targets as biologics,... |
| - | Orbis Medicines | “Orbis Medicines” |
Reviews 0
